|
paxil drug interaction Ness 1.4% 0.0% Somnolence 1.4% 0.0% In a placebo-controlled study of elderly patients with major depressive disorder paxil drug interaction, 13% (13 104) of patients treated with PAXIL CR discontinued due to an adverse event. Events meeting the above criteria included the following: PAXIL CR Placebo (n = 104) (n = 109) Nausea 2.9% 0.0% Headache 1.9% 0.9% Depression 1.9% 0.0% LFT’s abnormal 1.9% 0.0% Panic Disorder: Eleven percent (50 444) of patients treated with PAXIL CR in panic disorder studies discontinued treatment due to an adverse event. Events meeting the above criteria included the following: PAXIL CR Placebo (n = 444) (n = 445) Nausea 2.9% 0.4% Insomnia 1.8% 0.0% Headach paxil drug interaction.
paxil drug interaction E 1.4% 0.2% Asthenia 1.1% 0.0% Social Anxiety Disorder: Three percent (5 186) of patients treated with PAXIL CR in the social anxiety disorder study discontinued treatment due to an adverse event. Events meeting the above criteria included the following: PAXIL CR Placebo (n = 186) (n = 184) Nausea 2.2% 0.5% Headache 1.6% 0.5% Diarrhea 1.1% 0.5% Premenstrual Dysphoric Disorder: Spontaneously reported adverse events were monitored in studies of both continuous and intermittent dosing of PAXIL CR in the treatment of PMDD. Generally paxil drug interaction, there were few differences in the adverse event profiles of the 2 dosing regimens. Thirteen percent (88 681) of patients treated with PAXIL CR in PMDD studies of continuous dosing discontinued treatment due to an adverse event. The most common events (& 179; 1%) associated with discontinuation in either group treated with PAXIL CR with an incidence rate that is at least twice that of placebo in PMDD trials that employed a continuous dosing regimen are shown in the following table. This table also shows those events that were dose dependent (indicated with an asterisk) as defined as events having an incidence rate with 25 mg of PAXIL CR that was at least twice that with 12.5 mg of PAXIL CR (as well as the placebo group). PAXIL CR 25 mg (n = 348) PAXIL CR 12.5 mg (n = 333) Placebo (n = 34.
paxil drug interaction Th PAXIL CR in PMDD studies of continuous dosing discontinued treatment due to an adverse event. The most common events (& 179; 1%) associated with discontinuation in either group treated with PAXIL CR with an incidence rate that is at least twice that of placebo in PMDD trials that employed a continuous dosing regimen are shown in the following table. This table also shows those events that were dose dependent (indicated with an asterisk) as defined as events having an incidence rate with 25 mg of PAXIL CR that was at least twice that with 12.5 mg of PAXIL CR (as well as the placebo group). PAXIL CR 25 mg (n = 348) PAXIL CR 12.5 mg (n = 333) Placebo (n = 349.
paxil drug interaction 
paxil drug interaction | | | | | |
paxil drug interaction
|
